<DOC>
	<DOC>NCT00195572</DOC>
	<brief_summary>The purpose of the study is to verify non-inferiority of survival time between Isovorin/5-fluorouracil (1-LV/5FU) therapy and TS-1 therapy in patients with inoperable advanced or recurrent gastric cancer. Secondary endpoints include response rates, duration of responses, time to progression (TTP) safety and quality of life (QOL).</brief_summary>
	<brief_title>Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Gastric cancer diagnosed histologically or cytologically Normal organ function of bone marrow, heart, liver and kidney Age of 2077 Other inclusion applies Serious infection, heart disease, complication or organ disorder Ongoing administration of flucytosine Pregnant or breastfeeding women Other exclusion applies</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Advanced/Recurrent Gastric Cancer</keyword>
</DOC>